Could a higher dose of a common seizure drug better protect newborn brains?
NCT ID NCT05610085
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a higher-than-usual dose of the seizure medicine levetiracetam can safely stop seizures in newborns. About 133 full-term infants with seizures will first receive a standard dose, and if seizures continue, they will be randomly assigned to get either a higher dose of levetiracetam or the usual drug phenobarbital. The goal is to find the safest effective dose to control seizures and potentially reduce brain damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
levetiracetam (a seizure medicine)
What this could lead to
If successful, this could establish a safer, more effective dose of levetiracetam to control seizures in newborns, potentially reducing brain injury.
What could go wrong
This is an early-phase dose-finding study, so the best dose and safety are still unknown. The trial is small (133 infants) and results may not apply to all seizure types or severities.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOXIC ISCHEMIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Auckland City Hospital
RECRUITINGAuckland, Auckland, 1023, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Capital and Coast District Health Board, Te Whatu Ora, Health New Zealand
RECRUITINGWellington, Wellington Region, 6021, New Zealand
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Middlemore Hospital
RECRUITINGAuckland, Auckland, 1050, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Diego
RECRUITINGSan Diego, California, 92093, United States
Contact Email: •••••@•••••
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••